These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27402490)

  • 1. Sirtuins as modifiers of Parkinson's disease pathology.
    Tang BL
    J Neurosci Res; 2017 Apr; 95(4):930-942. PubMed ID: 27402490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.
    Neo SH; Tang BL
    Prog Mol Biol Transl Sci; 2018; 154():105-145. PubMed ID: 29413175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
    Outeiro TF; Kontopoulos E; Altmann SM; Kufareva I; Strathearn KE; Amore AM; Volk CB; Maxwell MM; Rochet JC; McLean PJ; Young AB; Abagyan R; Feany MB; Hyman BT; Kazantsev AG
    Science; 2007 Jul; 317(5837):516-9. PubMed ID: 17588900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking SIRT2 to Parkinson's disease.
    Garske AL; Smith BC; Denu JM
    ACS Chem Biol; 2007 Aug; 2(8):529-32. PubMed ID: 17708669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
    Zhang QS; Wang ZH; Zhang JL; Duan YL; Li GF; Zheng DL
    Biomed Pharmacother; 2016 Oct; 83():153-159. PubMed ID: 27470562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial Sirtuins in Parkinson's Disease.
    He L; Wang J; Yang Y; Li J; Tu H
    Neurochem Res; 2022 Jun; 47(6):1491-1502. PubMed ID: 35220492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirtuin dysregulation in Parkinson's disease: Implications of acetylation and deacetylation processes.
    Dhiman S; Mannan A; Taneja A; Mohan M; Singh TG
    Life Sci; 2024 Apr; 342():122537. PubMed ID: 38428569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitophagy: the latest problem for Parkinson's disease.
    Vives-Bauza C; Przedborski S
    Trends Mol Med; 2011 Mar; 17(3):158-65. PubMed ID: 21146459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
    Esteves AR; Gozes I; Cardoso SM
    Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Animal models for familial Parkinson's disease].
    Takahashi R
    Rinsho Shinkeigaku; 2007 Nov; 47(11):938-40. PubMed ID: 18210841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson's disease.
    Zhou ZD; Tan EK
    Ageing Res Rev; 2020 Sep; 62():101107. PubMed ID: 32535274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose.
    Li J; Li S; Zhang L; Ouyang L; Liu B
    Oncotarget; 2015 Dec; 6(38):40480-95. PubMed ID: 26415234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease.
    Todd AM; Staveley BE
    Genome; 2008 Dec; 51(12):1040-6. PubMed ID: 19088817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicine. The yin-yang of sirtuins.
    Dillin A; Kelly JW
    Science; 2007 Jul; 317(5837):461-2. PubMed ID: 17656709
    [No Abstract]   [Full Text] [Related]  

  • 18. New agents promote neuroprotection in Parkinson's disease models.
    Santos CM
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):410-8. PubMed ID: 22483311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.